A Mayo Clinic-led team of researchers is solving one of the most frustrating aspects of genetic cancer screening — results that give zero guidance to patients on whether they are at elevated risk.

CHICAGO (Reuters) - Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that ...

Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.

Scientists have analyzed thousands of mutations in the BRCA2 cancer gene, offering crucial insights. This research could help mitigate patient concerns or guide tailored treatments. By utilizing ...

A groundbreaking study led by the Mayo Clinic Comprehensive Cancer Center has significantly deepened our understanding of ...

A recent study that focused on women under 55 years old found an increase in pancreatic cancer cases. Mercy Medical Center Dr ...

"I just wish someone had told me this was a possibility." Kara Maxwell distinctly remembers the moment she heard those words ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center ...

Recent studies have identified risks in BRCA2 gene mutations, leading to better cancer risk assessment and treatment. Other ...

For the first time in Nepal, genetic testing, also known as "Gene Sequencing," related to breast cancer (BRCA1 and BRCA2) has ...

“These findings demonstrate the value of collaborative research in advancing our understanding of BRCA2 variants, improving classification methods that support more accurate risk assessments and ...

Get Instant Summarized Text (Gist) A comprehensive study has advanced the understanding of BRCA2 gene variants, crucial for assessing hereditary cancer risk. By functionally assessing nearly 7,000 ...